699852 | 3D-PHAD®
Monophosphoryl 3-Deacyl Lipid A (Synthetic)Pat No. 9,241,988
3D-PHAD®
Monophosphoryl 3-Deacyl Lipid A (Synthetic)Pat No. 9,241,988
Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD®), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.
The highly pure MPLA analog, 3D-PHAD®, provides a homogeneous synthetic equivalent for the 3-deacylated MPLA derived from bacterial LPS. While comparable to bacterial MPLA and other synthetic MPLA analogs at eliciting an immune response in a liposomal adjuvant system (see bar graph), 3D-PHAD® is less pyrogenic than its bacterial-derived mimic. Extensive preclinical testing with 3D-PHAD® demonstrated equivalency to PHAD®, and human trials have been scheduled for launch. 3D-PHAD® is protected under Pat No. 9,241,988. Licensing opportunities are available for vaccine or immunotherapy commercialization.
Stimulatory effect of PHAD®, 3D-PHAD®, and 3D(6-acyl)-PHAD® on macrophages. Macrophage cell line J774 cells were cultured with Avanti PHAD®, 3D-PHAD®, or 3D(6-acyl)-PHAD® for 24hrs. IL-12 levels in supernatants were measured by sandwich ELISA.
Adjuvant Activity
PHAD®, 3D-PHAD®, and 3D(6A)-PHAD® have been tested extensively in animals using a variety of antigens. In all cases, these adjuvants exhibit a similar activity and safety profile to bacterially-derived MPL. The data above demonstrate the equivalency of the three synthetic adjuvants to the bacterially-derived MPL when presented in a liposomal carrier system (DMPC/DMPG/Cholesterol).
- ChemDraw File
- 3D Structure
- Structure
- Brochure
- 699852 Adjuvant Data
- Safety Data Sheet
Singh P, Matyas GR, Anderson A, Beck Z. Biophysical characterization of polydisperse liposomal adjuvant formulations. Biochem Biophys Res Commun. 2020 Aug 20;529(2):362-365. doi: 10.1016/j.bbrc.2020.05.156. Epub 2020 Jul 1. PMID: 32703436.
PubMed ID: 32703436Martin ML, Bitzer AA, Schrader A, Bergmann-Leitner ES, Soto K, Zou X, Beck Z, Matyas GR, Dutta S. Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin. Malar J. 2019 Nov 27;18(1):377. doi: 10.1186/s12936-019-3014-5.
PubMed ID: 31775762Hernandez A, Luan L, Stothers CL, Patil NK, Fults JB, Fensterheim BA, Guo Y, Wang J, Sherwood ER, Bohannon JK. Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens. Crit Care Med. 2019 Nov;47(11):e930-e938. doi: 10.1097/CCM.0000000000003967.
PubMed ID: 31567352Beugeling M, De Zee J, Woerdenbag HJ, Frijlink HW, Wilschut JC, Hinrichs WLJ. Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly. Expert Rev Vaccines. 2019 Sep;18(9):935-950. doi: 10.1080/14760584.2019.1657013. Epub 2019 Aug 25.
PubMed ID: 31446807Singh P, Bodycomb J, Travers B, Tatarkiewicz K, Travers S, Matyas GR, Beck Z. Particle size analyses of polydisperse liposome formulations with a novel multispectral advanced nanoparticle tracking technology. Int J Pharm. 2019 Jul 20;566:680-686. doi: 10.1016/j.ijpharm.2019.06.013. Epub 2019 Jun 6.
PubMed ID: 31176851Smith RJ, Bryant RG. Metal substitutions incarbonic anhydrase: a halide ion probe study. Biochem Biophys Res Commun. 1975 Oct 27;66(4):1281-6.
PubMed ID: 31043512Cawlfield A, Genito CJ, Beck Z, Bergmann-Leitner ES, Bitzer AA, Soto K, Zou X, Hadiwidjojo SH, Gerbasi RV, Mullins AB, Noe A, Waters NC, Alving CR, Matyas GR, Dutta S. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ). Vaccine. 2019 Jun 27;37(29):3793-3803. doi: 10.1016/j.vaccine.2019.05.059. Epub 2019 May 28.
PubMed ID: 31151801Taleghani N, Bozorg A, Azimi A, Zamani H. Immunogenicity of HPV and HBV vaccines: adjuvanticity of synthetic analogs of monophosphoryl lipid A combined with aluminum hydroxide. APMIS. 2019 Mar;127(3):150-157. doi: 10.1111/apm.12927.
PubMed ID: 30746792- Certificate of Analysis(Lot No. 699852P-1MG-A-012and 5089PGA012)
- Certificate of Analysis(Lot No. 699852P-5MG-A-012and 5089PHA012)
- Certificate of Analysis(Lot No. 699852P-1MG-B-012and 5089PGB012)
- Certificate of Analysis(Lot No. 699852P-5MG-B-012and 5089PHB012)
- Certificate of Analysis(Lot No. 699852P-1MG-B-013and 5089PGB013)
- Certificate of Analysis(Lot No. 699852P-5MG-A-013and 5089PHA013)
- Certificate of Analysis(Lot No. 699852P-1MG-C-013and 5089PGC013)
- Certificate of Analysis(Lot No. 699852P-1MG-D-013and 5089PGD013)
- Certificate of Analysis(Lot No. 699852P-5MG-B-013and 5089PHB013)
- Certificate of Analysis(Lot No. 699852P-5MG-C-013and 5089PHC013)
- Certificate of Analysis(Lot No. 699852P-1MG-E-013and 5089PGE013)
- Certificate of Analysis(Lot No. 699852P-5MG-G-013and 5089PHG013)
- Certificate of Analysis(Lot No. 699852P-5MG-I-013and 5089PHI013)
- Certificate of Analysis(Lot No. 699852P-5MG-H-013and 5089PHH013)
AvantiPolarLipids公司是美国著名的磷脂类产品的生产商,该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。为世界范围内的研究机构和制药公司提供1000种以上脂类产品,由于其产品的高纯度而享誉全球。40年来,AvantiPolarLipids公司为世界各地的研究人员和制药公司提供脂类产品。公司的产品不仅范围日益扩大,其纯度之高也是无人能及。 AvantiPolarLipids,Inc.,hasalonghistoryof50yearscreatingthehighestpuritylipidsavailable.Ourpassionforhighqualityanduniqueproductsisonlyexceededbyourexcellentreputationinthemarketplace. Althoughweareknownforourlipids,weareMorethanLipids.Weoffersolutionsfortheentireproductcycle…ResearchtoCommercialization. AvantiPolarLipids公司的主要产品和服务包括:(1)ResearchProductsHighestPurityLipidReagents(2)cGMPManufacturingAPI&ContractManufacturing(3)AdjuvantsImmunotherapy&VaccineDevelopment(4)AnalyticalServicesLipidAnalysis(5)LipidomicsMassSpecStandards,Antibodies&LipidToolbox(6)Formulationsliposomes&Nanoparticles(7)EquipmentLiposomeProductionTools(8)CustomServicesSynthesis&Beyond
AvantiPolarLipids是美国著名的磷脂类产品的生产商,该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。为世界范围内的研究机构和制药公司提供1000种以上脂类产品,由于其产品的高纯度而享誉全球。40年来,AvantiPolarLipids公司为世界各地的研究人员和制药公司提供脂类产品。公司的产品不仅范围日益扩大,其纯度之高也是无人能及。
AvantiPolarLipidsInc,是美国著名的磷脂类产品的生产商,该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至百公斤级的磷脂类和甾体类中间体和试剂。主要产品Naturalsphingolipids天然鞘脂类Naturalphospholipids天然磷脂类Naturallipidsbyextraction天然提取脂类Referencestandards相关标准品Syntheticsphingolipids合成鞘脂类--Sphingosines&S-1-P鞘氨醇和鞘氨醇-1-磷酸盐--Ceramides神经酰胺--Sphingomyelins鞘磷脂--Sphingosine&ceramidederivatives鞘氨醇及神经酰胺衍生物--Sphinganine&derivatives鞘氨醇及其衍生物--C17sphingolipids十七碳鞘脂类--C20sphingolipids二十碳鞘脂类--Phytosphingosine&derivatives植物鞘氨醇及其衍生物Syntheticlipids&phospholipids合成脂质与磷脂--PC卵磷脂--PA磷脂酸--PE脑磷脂--PG磷脂酰甘油--PS磷脂酰丝氨酸--PI,PIP2&PIP3磷脂酰肌醇,磷脂酰肌醇-4,5-二磷酸,磷脂酰-3,4,5-三磷酸--CA胆酸--LysoPC溶源性卵磷脂--LysoPA溶源性磷脂酸--LysoPAAnalogues溶源性磷脂酸类似物--Lysobio-PA溶源性双磷脂酸--LysoPE,PG&PS溶源性脑磷脂,磷脂酰甘油和磷脂酰丝氨酸--AlkylPC烷基卵磷脂--Diether&Diphytanoyletherlipids二醚与二植烷醚脂质--PAF血小板活化因子--AcylPAFAnalog酰化血小板活化因子类似物--Brominatedphosphocholines溴代胆碱磷酸--Alkylphosphatederivatives烷基磷酸盐衍生物--Plasmalogen缩醛磷脂--Functionalizedlipids功能性脂类--Biotinylatedlipids生物素酰化脂质--Bioactivelipids生物活性脂类Syntheticphospholipids合成磷酸--AcylcoenzymeA乙酰辅酶A--Metabolicintermediates代谢中间产物--Adhesivelipid粘合脂质--pHsensitivelipids酸度计用脂质Transfectionreagents转染试剂Sterolderivatives甾酮衍生物Lipidblends混合脂质Glycosylatedphospholipids糖化磷脂Fluorinatedphospholipids氟化磷脂Chelators螯合剂Pre-mixedlipidsforbicelleformation构型分析用预混合脂质Diacylglycerols&analogues甘油二酯与类似物Deuteriumlabeledlipids氘标记脂质C13PC碳-13标记卵磷脂DoxylPC自旋标记卵磷脂TempoPCTempo(4-氧-4-羟-四甲基呱啶氮氧自由基)标记卵磷脂Fluoresecentsphingolipids荧光标记鞘脂类--Omegalabeled欧米加标记物--Fattyacidlabeled脂肪酸标记物Fluoresecentcholesterol荧光标记胆固醇Fluoresecentphospholipids荧光标记磷脂--Fattyacidlabeled脂肪酸标记物--Headgrouplabeled首基标记物Polymerizablelipids聚合脂质Poly(Ethyleneglycol)-lipidconjugates共轭聚脂质FunctionalizedPEGlipids功能PEG脂质Analyticalservices分析服务Drugdeliveryproduct药物运送载体Bulklipidsforpharmaceuticalproduction工业级脂质Equipment设备
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
1.我利用微乳法制备SLN,模型药物、三棕榈酸甘油酯、甘油、泊洛沙姆188,80度下融化,混合均匀,2000rpm搅拌状态下滴加1%PVA水相。冷却至室温时,表面有一层脂质析出。不断增加Lipid:surfacant的比例,当达到1:20时,当冷却至室温时,仍有脂质析出。
新人一枚,想问下各位大侠,有什么好的解决方案不?
我们使用了南京建成的胆固醇,甘油三酯和游离脂肪酸的试剂盒,样本为小鼠肝脏,试剂盒提供的步骤为使用生理盐水或者乙醇作为匀浆介质,3500rpm,10min;
然而我们发现生理盐水作为匀浆介质时,按此离心速度无法获得上清液;若加大离心速度以及延长离心时间,获得的上清液为白色,蛋白浓度检测出来浓度很高,效果十分不理想;若改为乙醇作为匀浆介质时,检测结果甘油三酯很高,游离脂肪酸浓度很低,不知是否涉及脂肪酯化的问题;
希望大家能给我提提建议,给点自己的妙招;或者是否有人提供好用的试剂盒?